Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoVAX in resected stage II/III colon cancer
NCT00016133Phase 2Completed
- Sponsor
- Intracel
- Start
- Mar 2001
- Modality
- Vaccines & Immunotherapeutics, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label trial of OncoVAX in colon cancer (2 arms), sponsored by Intracel. Primary endpoints: Safety of adjuvant autologous tumor cell vaccine and Immunogenicity of adjuvant autologous tumor cell vaccine. Started Mar 2001; status: completed.
02
Drugs
OncoVAX
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00016133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016133.